BVS
Bioventus Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-05
Figures on this page computed 2026-11-08 12:24 UTC
Last close
10.61USD
Market data, 2026-11-06
Except where said otherwise: 10-K for 2025, filed 2026-03-05
31.2xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001665988-26-000011
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-05
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001665988-26-000011
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-11-02
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-11-02
4.0%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001665988-26-000011
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
12.7%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001665988-26-000011
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-K for 2025, filed 2026-03-05
1.69Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0001665988-26-000011
- Reported in
- USD
- 10-K for 2025, filed 2026-03-05
- 10-Q for 2025, filed 2026-11-02
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Safety is the furthest below its sector's middle: 0.36 against 0.58 on the market's range.
- Growth12.1%75 of 100, above its sector
- Returns on capital12.3%71 of 100, above its sector
- Margins68.3%70 of 100, above its sector
- Price31.2x47 of 100, above its sector
- Safety1.6936 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 2 of 4- Profit on each unit of sales4%-2.2%Ahead
Higher is better here.
- Return on the capital it usesn/an/an/a
Higher is better here.
- Sales growth over five years12.1%25.2%Behind
Higher is better here.
- Debt against equity1.691.25Behind
Lower is better here.
- Gross margin68.3%18.8%Ahead
Higher is better here.
- Price against earnings31.2xn/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against AdaptHealth Corp., BVS is behind on 2 of 4 measures.
Against AdaptHealth Corp., BVS is behind on 2 of 4 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-03-05
Profit on each unit of sales4.0%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001665988-26-000011
- Reported in
- USD
Return on the capital it usesn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001665988-26-000011
- Reported in
- USD
Sales growth over five years12.1%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001665988-26-000011
- Reported in
- USD
Debt against equity1.69
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001665988-26-000011
- Reported in
- USD
Gross margin68.3%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001665988-26-000011
- Reported in
- USD
Price against earnings31.2x
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0001665988-26-000011
- Reported in
- USD